Treatment
Cell clinical trials
We’re tracking 5,682 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT06960993Recruiting
Mosaic trial for stem cell transplant patients
This trial tests a website designed to help patients learn about stem cell transplants for blood cancers. It aims to support you during your transplant journey.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06961617RecruitingPhase 1
Immune cell therapy for advanced hepatitis B-related liver cancer
This trial tests a new immune cell therapy (LioCyx-M) for people with advanced liver cancer caused by hepatitis B. It uses specially designed T cells (a type of immune cell) that target the hepatitis B virus and may help fight the cancer.
BeijingAges 18–70 - NCT06963307Recruiting
Blood test for early lung cancer detection
This study is testing a new blood test that looks for changes in DNA to detect lung cancer early. It's for people with a new lung cancer diagnosis, those with uncertain CT scan results, healthy volunteers, or those with chronic lung problems.
Ramat GanAges 18 years+ - NCT06964737RecruitingPhase 1
CAR T-cell therapy for recurrent brain tumors
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called GARP on your tumor cells. It is for people whose high-grade glioma (a fast-growing brain tumor) has come back after previous treatment.
Columbus, OhioAges 18 years+ - NCT06967038RecruitingPhase 1/Phase 2
Natural killer cell therapy for high-risk lymphoma with Sjogren's syndrome
This trial tests a new type of immune cell therapy using natural killer cells to treat people who have both high-risk lymphoma and primary Sjogren's syndrome. The goal is to see if these cells can safely and effectively fight the lymphoma while managing the autoimmune condition.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06975865RecruitingPhase 3
Rilzabrutinib for sickle-cell disease pain episodes
This study tests an oral medicine called rilzabrutinib to see if it can reduce painful episodes in people with sickle-cell disease. It may be an option if you have regular pain crises and are looking for a new treatment.
Birmingham, AlabamaAges 10–65 - NCT06977711RecruitingPhase 1
Testing a new drug combo for high-risk DLBCL
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
San Antonio, TexasAges 18 years+ - NCT06978647RecruitingPhase 1
YTS109 cell therapy for stubborn autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
Beijing, Beijing MunicipalityAges 18–65 - NCT06979492RecruitingPhase 4
Blood transfusions for pregnant women with sickle cell disease
This study tests whether giving regular blood transfusions during early pregnancy can help prevent complications for women with sickle cell disease. If you are between 6 and 20 weeks pregnant, you may join to see if this treatment improves outcomes.
Atlanta, GeorgiaAges 18 years+ - NCT06981325RecruitingPhase 2
Cemiplimab for advanced basal cell carcinoma
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
ErfurtAges 18 years+ - NCT06983899Recruiting
Exercise to boost immunity during lung cancer immunotherapy
This trial tests whether a supervised exercise program can help improve immune activity and treatment outcomes for people with non-small cell lung cancer who are already on immunotherapy. It is designed for people who are not currently very active.
Seattle, WashingtonAges 18 years+ - NCT06987916RecruitingPhase 1/Phase 2
Testing new immune cell therapy for B-cell lymphoma
This trial tests a new immune cell treatment (called U01 or ssCART-19) for people with B-cell lymphoma that has come back or not responded to other treatments. It aims to see if the therapy is safe and effective.
Shanghai, Shanghai MunicipalityAges 2–75 - NCT06988956RecruitingPhase 2
Nimotuzumab Plus Chemoradiation for Older Adults with Esophageal Cancer
This trial tests adding nimotuzumab, a targeted therapy, to standard chemoradiation for elderly patients with esophageal squamous cell cancer. It aims to see if the combination improves outcomes.
NanjingAges 75 years+ - NCT06992739RecruitingPhase 2
Trilaciclib with chemotherapy for EGFR-mutant advanced lung cancer
This study tests whether adding trilaciclib to a new chemotherapy (sacituzumab tirumotecan) can help people with EGFR-mutant lung cancer that keeps growing after certain targeted treatments. The goal is to see if it slows the cancer and reduces side effects.
Xiamen, FujianAges 18–75 - NCT06995508RecruitingPhase 2
Olanzapine for appetite loss in head and neck cancer patients
This trial tests if the drug olanzapine can help improve appetite in people with head and neck cancer who are getting chemotherapy and radiation. It aims to prevent or reduce weight loss during treatment.
Buffalo, New YorkAges 18 years+ - NCT06996782RecruitingPhase 1/Phase 2
Lung cancer study testing new combination treatments
This study tests a new drug (rilvegostomig) alone or with chemotherapy or another drug (ramucirumab) for advanced non-small cell lung cancer that has spread. It aims to see if these combinations work better than standard treatments.
Phoenix, ArizonaAges 18 years+ - NCT06998342RecruitingPhase 2
Mohs surgery plus short radiation for head and neck skin cancer
This trial studies a combination of Mohs surgery and a short course of radiation therapy for people with squamous cell skin cancer of the head and neck. The goal is to see if this approach is effective with fewer side effects.
Burlington, VermontAges 18 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Denver, ColoradoAges 18 years+ - NCT07000747Recruiting
Dengue and sickle cell disease study
This study looks at how severe dengue fever affects people with sickle cell disease. It aims to understand why some people with sickle cell get very sick from dengue and how their cells react.
Pointe-à-PitreAges 6–25 - NCT07001059Recruiting
Ultrasound to see nerve swelling in giant cell arteritis
This trial uses an ultrasound to check for swelling around the optic nerve in people who may have giant cell arteritis (GCA). It aims to see if this test can help diagnose GCA faster.
Aix-en-ProvenceAges 50 years+ - NCT07001384RecruitingPhase 1
Alectinib and Duvelisib for ALK-positive anaplastic large cell lymphoma
This trial tests two oral targeted drugs—alectinib and duvelisib—for people whose ALK-positive anaplastic large cell lymphoma has come back or not responded after at least one prior chemotherapy. The goal is to see if this combination can help control the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT07001540RecruitingPhase 2
Targeted drug combo for relapsed DLBCL
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07001618RecruitingPhase 2
Fecal transplant with immunotherapy for advanced lung cancer
This trial tests whether taking an oral fecal transplant (MaaT033) along with the immunotherapy drug cemiplimab can help people whose lung cancer stopped responding after antibiotics. It's for people with advanced non-small cell lung cancer whose cancer got worse after standard immunotherapy.
DijonAges 18 years+ - NCT07001631Recruiting
EMDR for pain relief in children with sickle cell disease
This trial tests if EMDR therapy can help children with sickle cell disease reduce pain interference in daily life. If you or your child has sickle cell disease and experiences significant pain, this study may offer a new way to manage it.
AmsterdamAges 6–18
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,682 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.